Zhenfeng Duan

5.4k total citations
92 papers, 3.6k citations indexed

About

Zhenfeng Duan is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Zhenfeng Duan has authored 92 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Molecular Biology, 42 papers in Oncology and 37 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Zhenfeng Duan's work include Sarcoma Diagnosis and Treatment (28 papers), Cancer-related Molecular Pathways (15 papers) and Bone Tumor Diagnosis and Treatments (14 papers). Zhenfeng Duan is often cited by papers focused on Sarcoma Diagnosis and Treatment (28 papers), Cancer-related Molecular Pathways (15 papers) and Bone Tumor Diagnosis and Treatments (14 papers). Zhenfeng Duan collaborates with scholars based in United States, China and Thailand. Zhenfeng Duan's co-authors include Francis J. Hornicek, Dylan C. Dean, Henry J. Mankin, Edwin Choy, Jacson Shen, Michael V. Seiden, Pichaya Thanindratarn, Rosemary Foster, Hashem B. El‐Serag and Wenlong Feng and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Zhenfeng Duan

88 papers receiving 3.6k citations

Peers

Countries citing papers authored by Zhenfeng Duan

Since Specialization

Citations

This map shows the geographic impact of Zhenfeng Duan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhenfeng Duan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhenfeng Duan more than expected).

Fields of papers citing papers by Zhenfeng Duan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhenfeng Duan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhenfeng Duan. The network helps show where Zhenfeng Duan may publish in the future.

Co-authorship network of co-authors of Zhenfeng Duan

This figure shows the co-authorship network connecting the top 25 collaborators of Zhenfeng Duan. A scholar is included among the top collaborators of Zhenfeng Duan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhenfeng Duan. Zhenfeng Duan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mutational analysis of primary and advanced chordoma tissue using next‐generation sequencing 2025 ·Cancer ·(unknown), (unknown), Zhenfeng Duan, (unknown), Alireza Samiei, Scott D. Nelson, Arun S. Singh, Elizabeth L. Lord, Brooke Crawford, Nicholas M. Bernthal, Francis J. Hornicek	2
2	High-Throughput Drug Screening in Chondrosarcoma Cells Identifies Effective Antineoplastic Agents Independent of IDH Mutation 2024 ·International Journal of Molecular Sciences ·Luyuan Li, (unknown), Josiane E. Eid, Wensi Tao, (unknown), Amy Yu, Ammad Ahmad Farooqi, Hassan Al‐Ali, Gina Z. D’Amato, Francis J. Hornicek, Zhenfeng Duan, Ines Lohse, Jonathan C. Trent	0
3	Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma 2024 ·Biochemical Pharmacology ·Robert L. Walker, Francis J. Hornicek, Zhenfeng Duan	5
4	Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value 2020 ·European Spine Journal ·Pichaya Thanindratarn, Dylan C. Dean, Wenlong Feng, Ran Wei, Scott D. Nelson, Francis J. Hornicek, Zhenfeng Duan	11
5	Role of cyclin‐dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway 2019 ·Hepatology Research ·Shen Shen, Dylan C. Dean, Zujiang Yu, Zhenfeng Duan	40
6	Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma 2018 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Yubing Zhou, Jacson Shen, Zujiang Yu, Francis J. Hornicek, Quancheng Kan, Zhenfeng Duan	54
7	From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma 2018 ·Cancer and Metastasis Reviews ·Dylan C. Dean, Shen Shen, Francis J. Hornicek, Zhenfeng Duan	57
8	Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma 2018 ·Cell Death and Disease ·Xiaoyang Li, Nicole A. Seebacher, Cassandra C. Garbutt, (unknown), Peng Gao, Tao Xiao, Francis J. Hornicek, Zhenfeng Duan	28
9	Expression and Therapeutic Potential of SOX9 in Chordoma 2017 ·Clinical Cancer Research ·(unknown), Cassandra C. Garbutt, Dimitrios Spentzos, Edwin Choy, Francis J. Hornicek, Zhenfeng Duan	41
10	Application of metabolomics in sarcoma: From biomarkers to therapeutic targets 2017 ·Critical Reviews in Oncology/Hematology ·Li Min, Edwin Choy, Chongqi Tu, Francis J. Hornicek, Zhenfeng Duan	11
11	Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats 2016 ·Scientific Reports ·Yan Gao, Jacson Shen, Edwin Choy, Zhan Zhang, Henry J. Mankin, Francis J. Hornicek, Zhenfeng Duan	14
12	CSPG4 as a prognostic biomarker in chordoma 2015 ·The Spine Journal ·Andrew J. Schoenfeld, Xinhui Wang, Yangyang Wang, Francis J. Hornicek, G. Petur Nielsen, Zhenfeng Duan, Soldano Ferrone, Joseph H. Schwab	28
13	The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma 2015 ·Cancer and Metastasis Reviews ·Yunfei Liao, Yong Feng, Jacson Shen, Francis J. Hornicek, Zhenfeng Duan	34
14	Sleep duration and incidence of colorectal cancer in postmenopausal women 2013 ·British Journal of Cancer ·Li Jiao, Zhenfeng Duan, Haleh Sangi‐Haghpeykar, Lauren Hale, Donna L. White, Hashem B. El‐Serag	96
15	Tissue Microarray Immunohistochemical Detection of Brachyury Is Not a Prognostic Indicator in Chordoma 2013 ·PLoS ONE ·Linlin Zhang, Shang Guo, Joseph H. Schwab, G. Petur Nielsen, Edwin Choy, Shunan Ye, Zhan Zhang, Henry J. Mankin, Francis J. Hornicek, Zhenfeng Duan	36
16	miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo 2011 ·Oncogene ·Amy de Haar-Holleman, Ivy Chung, Rachelle R. Olsen, Brenda R. Kwak, Atsushi Mizokami, Nagahiro Saijo, Amadeo M. Parissenti, Zhenfeng Duan, Emile E. Voest, Bruce R. Zetter	87
17	Effects of Siltuximab on the IL-6–Induced Signaling Pathway in Ovarian Cancer 2010 ·Clinical Cancer Research ·Yuqi Guo, Jeffrey A. Nemeth, Conan J O O’Brien, Michiro Susa, Xianzhe Liu, Zhan Zhang, Edwin Choy, Henry J. Mankin, Francis J. Hornicek, Zhenfeng Duan	87
18	A novel target for treatment of chordoma: signal transducers and activators of transcription 3 2009 ·Molecular Cancer Therapeutics ·Yang Cao, Joseph H. Schwab, Andrew J. Schoenfeld, Francis J. Hornicek, Kirkham B. Wood, G. Petur Nielsen, Edwin Choy, Henry J. Mankin, Zhenfeng Duan	43
19	CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells 2008 ·Cancer Chemotherapy and Pharmacology ·Zhenfeng Duan, (unknown), Meagan B. Ryan, Francis J. Hornicek, Henry J. Mankin, Michael V. Seiden	65
20	Biphasic metaplastic sarcomatoid carcinoma of the breast 2006 ·Annals of Oncology ·Bryan T. Hennessy, Sharon H. Giordano, Kristine Broglio, Zhenfeng Duan, J.M. Trent, Thomas A. Buchholz, Gildy V. Babiera, Gabriel N. Hortobágyi, Vicente Valero	165

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact